Comparative study of efficacy and safety of erythropoietin and darbepoetin for treatment of anemia in chronic kidney disease patients: a comparative, observational and prospective study

Simple item page
dc.contributor.authorShah, BKen_US
dc.contributor.authorBhat, WHen_US
dc.contributor.authorGeorge, Jen_US
dc.contributor.authorRamaiah, Ben_US
dc.date.accessioned2025-06-18T11:23:11Z
dc.date.available2025-06-18T11:23:11Z
dc.date.issued2025-02
dc.description.abstractBackground: Anemia is a common prognosis of chronic kidney disease (CKD). It is predominantly managed with erythropoietin and darbepoetin. The objective of this study was to compare the efficacy and safety of erythropoietin injection versus darbepoetin for treating renal anemia amongst patient with CKD. Methods: Patients of either gender diagnosed with anemia due to CKD, irrespective of dialysis who had haemoglobin less than 12g/dl were included in the study. Comparison of efficacy and safety of erythropoietin and darbepoetin was done based on the laboratory values of hemoglobin (Hb), red blood cells (RBCs), haematocrit (PCV) and adverse events respectively. Results: A total of 108 patients met the inclusion criteria; 54 of them were treated with erythropoietin and 54 were treated with darbepoetin. The changes in Hb, RBCs and PCV in the group of patients who were on erythropoietin were 1.16, 0.49 and 3.76 respectively. Similarly, the changes in Hb, RBCs and PCV in the group of patients who were on Darbepoetin were 1.19, 0.42 and 3.52 respectively. The differences in the changes of Hb, RBCs and PCV in the both groups of patients were 0.04, 0.07 and 0.24 respectively. A total of 4 adverse events (HTN, vomiting, headache and joint pain) were reported by 24 (44.44%) patients of erythropoietin group and a total of 1 adverse event (HTN) was reported by 19 (35.19%) patients of darbepoetin group. Conclusion: Both erythropoietin and darbepoetin were found to be equally effective and safe for the treatment of anemia in CKD patients.en_US
dc.identifier.affiliationsDepartment of Pharmacy, Karnataka College of Pharmacy, Bangalore, Karnataka, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy, Karnataka College of Pharmacy, Bangalore, Karnataka, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Karnataka College of Pharmacy, Bangalore, Karnataka, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Karnataka College of Pharmacy, Bangalore, Karnataka, Indiaen_US
dc.identifier.citationShah BK, Bhat WH, George J, Ramaiah B. Comparative study of efficacy and safety of erythropoietin and darbepoetin for treatment of anemia in chronic kidney disease patients: a comparative, observational and prospective study. International Journal of Basic & Clinical Pharmacology. 2025 Feb; 14(1): 45-49en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/248652
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume14en_US
dc.source.urihttps://doi.org/10.18203/2319-2003.ijbcp20243834en_US
dc.subjectAnemiaen_US
dc.subjectChronic kidney diseaseen_US
dc.subjectDarbepoetinen_US
dc.subjectErythropoietinen_US
dc.titleComparative study of efficacy and safety of erythropoietin and darbepoetin for treatment of anemia in chronic kidney disease patients: a comparative, observational and prospective studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijbcp2025v14n1p45.pdf
Size:
165.79 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology